Hirschberg, Angelica LindenBitzer, JohannesCano, AntonioCeausu, IulianaChedraui, PeterDurmuşoğlu, FatihErkkola, RistoGoulis, Dimitrios G.Kiesel, LudwigLopes, PatricePines, Amosvan Trotsenburg, MickLambrinoudaki, IreneRees, Margaret2021-06-172021-06-172021Hirschberg, A. L., Bitzer, J., Cano, A., Ceausu, I., Chedraui, P., Durmuşoğlu, F. ... Rees, M. (2021). Topical estrogens and non-hormonal preparations for postmenopausal vulvovaginal atrophy: An EMAS clinical guide. Maturitas, 148, 55-61. https://dx.doi.org/10.1016/j.maturitas.2021.04.0050378-51221873-4111https://dx.doi.org/10.1016/j.maturitas.2021.04.005https://hdl.handle.net/20.500.12511/7210Introduction: Vulvovaginal atrophy (VVA) is a chronic condition caused by estrogen deficiency. It affects around 50% of postmenopausal women, reducing their general and sexual quality of life as well as the quality of their personal relationships. Aim: The aim of this clinical guide is to set out an individualized approach to the management of VVA with topical estrogens and non-hormonal preparations. Materials and methods: Literature review and consensus of expert opinion. Summary recommendations: An individualized approach is required for the management of VVA. Topical low-dose estrogens are effective and also alleviate urinary incontinence and prevent recurrent urinary tract infections. Women should not be denied long-term use of topical estrogens as long as they feel that this treatment is of benefit to them, because the safety data are reassuring. Non-hormonal preparations (lubricants and moisturizers) should be the first-line treatment for VVA in women taking adjuvant endocrine therapies for cancers considered to be hormone-dependent. They can be used over the long term.eninfo:eu-repo/semantics/openAccessNon-Hormonal PreparationsTopical EstrogensVulvovaginal AtrophyArticle148556110.1016/j.maturitas.2021.04.005Q1Q1